-
Je něco špatně v tomto záznamu ?
Children and adolescents with marginal zone lymphoma have an excellent prognosis with limited chemotherapy or a watch-and-wait strategy after complete resection
L. Ronceray, O. Abla, S. Barzilai-Birenboim, S. Bomken, AK. Chiang, J. Jazbec, E. Kabickova, J. Lazic, A. Beishuizen, K. Mellgren, F. Tanaka, M. Pillon, C. Devalck, M. Gouttenoire, O. Makarova, B. Burkhardt, A. Attarbaschi, European Intergroup...
Jazyk angličtina Země Spojené státy americké
Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie, práce podpořená grantem
PubMed
29286565
DOI
10.1002/pbc.26932
Knihovny.cz E-zdroje
- MeSH
- dítě MeSH
- lidé MeSH
- lymfom z B-buněk marginální zóny mortalita patofyziologie terapie MeSH
- míra přežití MeSH
- mladiství MeSH
- následné studie MeSH
- předškolní dítě MeSH
- přežití bez známek nemoci MeSH
- retrospektivní studie MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
Data on management of pediatric marginal zone lymphoma (MZL) are scarce. This retrospective study assessed characteristics and outcome in 66 patients who were <18 years old. Forty-four (67%) had an extranodal MZL (EMZL), 21 (32%) a nodal MZL (NMZL), and one patient a splenic MZL. Thirty-three patients (50%) received a variable combination of adjuvant chemotherapy/immunotherapy/radiotherapy, while the remainder, including 20 of 21 with NMZL, entered an active observation period. Overall survival was excellent (98 ± 2%), although 11 patients relapsed (17%; NMZL, n = 1; EMZL, n = 10), seven after any therapy and four after complete resection only. In conclusion, outcome of NZML, in particular, seems to be excellent after (in)complete resection and observation only.
Department of Pediatrics Saiseikai Yokohamashi Nanbu Hospital Yokohama Japan
Northern Institute for Cancer Research Newcastle University Newcastle UK
Pediatric Hematology and Oncology Erasmus MC Sophia Children's Hospital Rotterdam The Netherlands
Pediatric Hematology and Oncology Hopital Universitaire des Enfants Reine Fabiola Brussels Belgium
Pediatric Hematology and Oncology University Hospital Saint Etienne France
Pediatric Hematology and Oncology University of Münster Münster Germany
Pediatric Hematology and Oncology University of Padova Padova Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028645
- 003
- CZ-PrNML
- 005
- 20190822091112.0
- 007
- ta
- 008
- 190813s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/pbc.26932 $2 doi
- 035 __
- $a (PubMed)29286565
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Ronceray, Leila $u Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.
- 245 10
- $a Children and adolescents with marginal zone lymphoma have an excellent prognosis with limited chemotherapy or a watch-and-wait strategy after complete resection / $c L. Ronceray, O. Abla, S. Barzilai-Birenboim, S. Bomken, AK. Chiang, J. Jazbec, E. Kabickova, J. Lazic, A. Beishuizen, K. Mellgren, F. Tanaka, M. Pillon, C. Devalck, M. Gouttenoire, O. Makarova, B. Burkhardt, A. Attarbaschi, European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) and the International Berlin-Frankfurt-Münster (i-BFM) Study Group,
- 520 9_
- $a Data on management of pediatric marginal zone lymphoma (MZL) are scarce. This retrospective study assessed characteristics and outcome in 66 patients who were <18 years old. Forty-four (67%) had an extranodal MZL (EMZL), 21 (32%) a nodal MZL (NMZL), and one patient a splenic MZL. Thirty-three patients (50%) received a variable combination of adjuvant chemotherapy/immunotherapy/radiotherapy, while the remainder, including 20 of 21 with NMZL, entered an active observation period. Overall survival was excellent (98 ± 2%), although 11 patients relapsed (17%; NMZL, n = 1; EMZL, n = 10), seven after any therapy and four after complete resection only. In conclusion, outcome of NZML, in particular, seems to be excellent after (in)complete resection and observation only.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lymfom z B-buněk marginální zóny $x mortalita $x patofyziologie $x terapie $7 D018442
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a míra přežití $7 D015996
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Abla, Oussama $u Division of Hematology and Oncology, Department of Pediatrics, Hospital for Sick Children, Toronto, Canada.
- 700 1_
- $a Barzilai-Birenboim, Shlomit $u Pediatric Hematology and Oncology, Schneider Children's Medical Center of Israel, Petah-Tivka, Israel. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- 700 1_
- $a Bomken, Simon $u Northern Institute for Cancer Research, Newcastle University, Newcastle, UK.
- 700 1_
- $a Chiang, Alan Ks $u Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong.
- 700 1_
- $a Jazbec, Janez $u Division of Pediatrics, Hematology and Oncology, University Medical Center Ljubljana, Ljubljana, Slovenia.
- 700 1_
- $a Kabickova, Edita $u Pediatric Hematology and Oncology, Charles University and University Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Lazic, Jelena $u Pediatric Hematology and Oncology, University Children's Hospital, School of Medicine University of Belgrade, Belgrade, Serbia.
- 700 1_
- $a Beishuizen, Auke $u Pediatric Hematology and Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
- 700 1_
- $a Mellgren, Karin $u Pediatric Hematology and Oncology, The Queen Silvia's Hospital for Children and Adolescents, University of Göteborg, Göteborg, Sweden.
- 700 1_
- $a Tanaka, Fumiko $u Department of Pediatrics, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan.
- 700 1_
- $a Pillon, Marta $u Pediatric Hematology and Oncology, University of Padova, Padova, Italy.
- 700 1_
- $a Devalck, Christine $u Pediatric Hematology and Oncology, Hopital Universitaire des Enfants Reine Fabiola, Brussels, Belgium.
- 700 1_
- $a Gouttenoire, Marina $u Pediatric Hematology and Oncology, University Hospital, Saint Etienne, France.
- 700 1_
- $a Makarova, Olga $u Pediatric Hematology and Oncology, University of Münster, Münster, Germany.
- 700 1_
- $a Burkhardt, Birgit $u Pediatric Hematology and Oncology, University of Münster, Münster, Germany.
- 700 1_
- $a Attarbaschi, Andishe $u Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.
- 710 2_
- $a European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) and the International Berlin-Frankfurt-Münster (i-BFM) Study Group
- 773 0_
- $w MED00181047 $t Pediatric blood & cancer $x 1545-5017 $g Roč. 65, č. 4 (2018)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29286565 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190822091351 $b ABA008
- 999 __
- $a ok $b bmc $g 1433794 $s 1067105
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 65 $c 4 $e 20171229 $i 1545-5017 $m Pediatric blood & cancer $n Pediatr Blood Cancer $x MED00181047
- LZP __
- $a Pubmed-20190813
